Helius Medical prices $6.4M public offering of stock and warrants

On May 6, 2024, Helius Medical Technologies, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Craig-Hallum Capital Group LLC (the “Placement Agent”) for the purchase and sale, in a registered public offering by the Company (the “Public Offering”) of 704,999 shares of its Class A common stock, par value $0.001 per share (“Common Stock”) and 2,147,222 pre-funded warrants, each to purchase one share of Common Stock at an exercise price of $0.001 per share (the “Pre-funded Warrants”) together with accompanying Series A Warrants to purchase up to 2,852,221 shares of its Common Stock (“Series A Warrants”) and Series B Warrants to purchase up to 2,852,221 shares of its Common Stock (“Series B Warrants”, and together with the Series A Warrants, the “Public Warrants”).